Literature DB >> 25682057

Managing unusual presentations of venous thromboembolism.

Walter Ageno1.   

Abstract

Venous thromboembolism that occurs in unusual sites is challenging because of the potential severity of presentation, the presence of some major provoking risk factors, the high prevalence of potential contraindications to antithrombotic therapies, the lack of solid evidence to guide therapeutic decisions, and because of the severity of long-term consequences. For example, venous thrombosis in the splanchnic veins frequently occurs in patients with liver cirrhosis. Not uncommonly, these patients present with concomitant active gastrointestinal bleeding, and/or low platelet count or oesophageal varices. If inadequately treated, splanchnic vein thrombosis (SVT) may further worsen portal hypertension and, thus, increase the long-term risk of bleeding. Up to 40% of patients with cerebral vein thrombosis (CVT) have signs of intracranial bleeding at the time of the diagnosis. This finding is associated with worst prognosis in terms of death or severe disability. Despite the apparent presence of a major contraindication to anticoagulation, only a timely administration of parenteral anticoagulant drugs may improve this unfavourable outcome. The available evidence on the management of these two challenging disorders, SVT and CVT, will be reviewed in this article.

Entities:  

Mesh:

Year:  2015        PMID: 25682057     DOI: 10.1007/s11239-015-1171-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  46 in total

1.  Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study.

Authors:  W Ageno; A Squizzato; A Togna; F Magistrali; M Mangini; C Fugazzola; F Dentali
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

2.  Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver.

Authors:  T P Almdal; T I Sørensen
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

Review 3.  Cerebral venous thrombosis: an update.

Authors:  Marie-Germaine Bousser; José M Ferro
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

Review 4.  Budd-Chiari syndrome: Radiologic findings.

Authors:  Patrick S Kamath
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

Review 5.  Anticoagulation for cerebral venous sinus thrombosis.

Authors:  Jonathan M Coutinho; Sebastiaan F T M de Bruijn; Gabrielle deVeber; Jan Stam
Journal:  Stroke       Date:  2012-04       Impact factor: 7.914

6.  Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.

Authors:  Ida Martinelli; Paolo Bucciarelli; Serena M Passamonti; Tullia Battaglioli; Emanuele Previtali; Pier Mannuccio Mannucci
Journal:  Circulation       Date:  2010-06-14       Impact factor: 29.690

7.  Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis.

Authors:  Jonathan M Coutinho; José M Ferro; Patrícia Canhão; Fernando Barinagarrementeria; Marie-Germaine Bousser; Jan Stam
Journal:  Stroke       Date:  2010-10-07       Impact factor: 7.914

8.  How I treat splanchnic vein thrombosis.

Authors:  Walter Ageno; Francesco Dentali; Alessandro Squizzato
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

9.  Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience.

Authors:  Rupesh Rajani; Tor Melin; Einar Björnsson; Ulrika Broomé; Per Sangfelt; Ake Danielsson; Anders Gustavsson; Olof Grip; Hans Svensson; Lars Lööf; Sven Wallerstedt; Sven H C Almer
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

10.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.